MILAN--(BUSINESS WIRE)--Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today it has received CE (Conformité Européenne) Mark approval for the XL version of Perceval. Perceval is a bioprosthetic device designed to replace a diseased native or malfunctioning prosthetic aortic valve using either traditional or minimally invasive heart surgery. Perceval implant is easy(1), safe(1,2) and reproducible(3) due to the unique technology that allows sutureless positioning and anchoring at the implantation site. This approval expands the Perceval portfolio, permitting cardiac surgeons to treat patients with annulus sizes ranging from 19 mm to 27 mm.
Help employers find you! Check out all the jobs and post your resume.
